SCHEMBL4367203

SCHEMBL4367203

O=C(O)[C@H](Cc1ccc(C(F)(F)F)cc1)N=C(c1ccccc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.52
PPARA Q07869 4/20 0.52
FPR2 P25090 1/20 0.45
AAK1 Q2M2I8 1/20 0.45
PDPK1 O15530 2/20 0.45
EPHX2 P34913 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PTPN1 P18031 2/20 0.42
MDM2 Q00987 1/20 0.41
SRD5A2 P31213 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
GRB2 P62993 1/20 0.40
MAPK14 Q16539 1/20 0.40
CTSD P07339 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118063 0.85 PPARG (0.50) PPARGPPARAAAK1MDM2
SCHEMBL1193057 0.85 PPARG (0.50) PPARGPPARAAAK1MDM2
SCHEMBL30949486 0.84 AAK1 (0.65) PPARGPPARAAAK1PDPK1EPHX2
SCHEMBL20166245 0.83 AAK1 (0.43) PPARGPPARAAAK1EPHX2NPC1
SCHEMBL4368334 0.83 FPR2 (0.48) PPARGPPARAFPR2AAK1EPHX2
SCHEMBL4367158 0.83 FPR2 (0.48) PPARGPPARAFPR2AAK1EPHX2
SCHEMBL20166244 0.83 AAK1 (0.43) PPARGPPARAAAK1EPHX2NPC1
SCHEMBL22033163 0.82 SLC7A5 (0.47) PPARGPPARAAAK1RAB9AMDM2
SCHEMBL22033162 0.82 SLC7A5 (0.47) PPARGPPARAAAK1RAB9AMDM2
SCHEMBL29254130 0.81 PPARG (0.49) PPARGPPARAL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908466-B1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO CO LTD (JP) 2014-02-19 EP disclosed
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
EP-1908466-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME PTMS, C1S, ACP3 PPARG 1696/4885PPARA 941/4885FPR2 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.